La Chaux-de-fonds, RH Neuchatelois (Hopital Les Cadolles)
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Auteri, Agnes
REDUSE, NCT02051218 / 2014-001189-87: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Active, not recruiting
3
1380
Europe
Denosumab (reduced dosing), XGEVA®, Denosumab (standard dosing)
Swiss Group for Clinical Cancer Research
Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
06/26
12/28
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Auteri, Agnes
REDUSE, NCT02051218 / 2014-001189-87: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Active, not recruiting
3
1380
Europe
Denosumab (reduced dosing), XGEVA®, Denosumab (standard dosing)
Swiss Group for Clinical Cancer Research
Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
06/26
12/28
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26

Download Options